Tarsus (TARS) COO Neervannan Seshadri Sells 4,564 Shares

What Happened Neervannan Seshadri, Chief Operating Officer of Tarsus Pharmaceuticals, sold 4,564 shares of TARS on September 4, 2026 at $85.00 per share, generating gross proceeds of $387,940. The sale was reported on Form 4 filed September 9, 2026 and was effected under an automatic Rule 10b5-1 trading plan.

Key Details

• Transaction date and price: 2026-09-04 — 4,564 shares at $85.00 each; proceeds $387,940.
• Transaction type: Sale (open market or private sale) reported as code S.
• Plan/notes: Sale executed pursuant to a Rule 10b5-1 plan adopted by the reporting person on Nov 13, 2025 (footnote F1).
• Holdings and footnotes: Filing notes 305 shares were acquired under the issuer’s ESPP on 2026-06-30 (F2). A holding balance related to the reporting person’s daughter is disclosed and the reporting person disclaims beneficial ownership of those securities (F3). The specific "shares owned following the transaction" value is not provided in the excerpt.
• Filing timeliness: Report filed on 2026-09-09; based on the Sep 4 trade date this filing appears to be timely.

Context Sales made under pre-established 10b5-1 plans are typically automated and do not necessarily reflect the insider’s current view of the company. For retail investors, purchases generally carry clearer positive signals than routine sales; this single planned sale should be viewed as a liquidity/plan-based transaction unless accompanied by additional insider activity.